Tiopronin enteric-coated microtablets and preparation method thereof

By using specific composition particles and coatings in thiopronin enteric-coated microsheets and adopting appropriate preparation technology, the problems of uneven composition content and unreasonable dissolution are solved, and high-quality thiopronin enteric-coated microsheets are achieved. Microfilm preparation is suitable for use by the elderly and children, and improves economic benefits.

CN117838640BActive Publication Date: 2024-11-22HQ PHARMA (SHANGHAI) CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202311661371.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-06
Publication Date
2024-11-22
Estimated Expiration
2043-12-06

AI Technical Summary

Technical Problem

The prior art cannot effectively solve the problems of uneven composition content, unreasonable dissolution and unstable quality during the preparation process of thiopronin enteric-coated microsheets.

Method used

Use particles composed of thiopronin, filler, adhesive, disintegrant, lubricant, and coated by film forming agent, enteric coating, anti-adhesive agent, plasticizer, and fluidized bed, Wet or dry pressure mechanism preparation process to prepare thiopronin enteric-coated microsheets with a diameter of 1-3 mm.

Benefits of technology

It achieves good uniformity in tablet weight distribution, rapid and complete dissolution behavior, improves the quality of the drug and patient experience, and is especially suitable for the elderly and children to take, and the preparation process is simple, cost-effective and efficient.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004590318910000101
    Figure BDA0004590318910000101
  • Figure BDA0004590318910000151
    Figure BDA0004590318910000151
  • Figure BDA0004590318910000161
    Figure BDA0004590318910000161
Patent Text Reader

Abstract

The present invention provides a tiopronin enteric-coated microtablet and a preparation method, and belongs to the technical field of pharmaceutical preparations. The tiopronin enteric-coated microtablet provided by the present invention is composed of particles and coatings, wherein the particles are composed of tiopronin, a filler, a binder, a disintegrant, and a lubricant; the coating is composed of a film-forming agent, an enteric coating, an anti-adhesive agent, and a plasticizer. The present invention also provides a preparation method of the tiopronin enteric-coated microtablet. Compared with the existing tiopronin enteric-coated tablets, the tiopronin enteric-coated microtablet provided by the present invention has the advantages of both ordinary tablets and micropills, has accurate dosage, is easy to swallow, can improve patient compliance, and has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations and relates to a tiopronin enteric-coated microtablet and a preparation method thereof. Background Art

[0002] Tiopronin, chemical name: N-(2-mercaptopropionyl)glycine. Molecular formula: C5H9NO3S. Tiopronin is rapidly absorbed in the intestine after oral administration, with a bioavailability of 85% to 90%. It is metabolized in the liver, most of which is metabolized into inactive substances. It is suitable for cystinuria. Clinically, Tiopronin can convert urinary cystine into a more soluble form and reduce the saturation of urinary cystine. Therefore, Tiopronin can prevent the formation of new stones and dissolve cystine stones.

[0003] Tiopronin is a soluble drug with high oral bioavailability. Invention patent CN103570596A relates to a method for low-temperature recrystallization of crude Tiopronin, which can significantly improve the stability of a new Tiopronin crystalline compound.

[0004] Tiopronin was first developed by Santen Pharmaceutical Co., Ltd. in Japan and was first launched in Japan in 1964 under the trade name Thiola. It was subsequently launched in dozens of countries including Germany, Italy, the United States and Switzerland, and was approved for marketing in China by the Ministry of Health in 1995. Currently, no similar dosage form is available on the market.

[0005] Mini-tablets (abbreviated as micro-tablets) are usually less than 3mm in diameter and are generally multi-unit preparations. Micro-tablets have the advantages of being easy to swallow, accurate in dosage, and flexible in dosage adjustment, and are suitable for children, patients with dysphagia, and the like. According to clinical needs, micro-tablets can be developed into immediate-release, sustained-release, enteric-coated micro-tablets, etc.; they can be filled in capsules, bags, and bottles, and a tablet counter can be configured as needed to measure the number of micro-tablets to be administered. Based on the characteristics of the dosage form and clinical treatment needs, when selecting excipients, attention should be paid to functional indicators such as fluidity and compressibility of the excipients. For sulpronin, attention should be paid to indicators such as crystal form, density, particle size, and distribution that affect fluidity. Micro-tablets can be coated for the need to improve palatability, change the dissolution behavior of the drug, or for production needs. The production process of micro-tablets is the same as that of ordinary tablets, and usually uses processes such as direct powder compression, wet granulation tableting, dry granulation tableting, and fluidized bed granulation tableting. Microtablets have higher requirements for production and quality control than ordinary tablets, but the use of the above-mentioned preparation process will make it difficult to control the content uniformity of the microtablets, and it is easy to produce products with unqualified content uniformity. Therefore, the invention of a sulpronine microtablet with stable product quality, reliable efficacy, qualified content uniformity, reasonable dissolution and simple preparation process has significant economic and social benefits.

[0006] Compared with conventional tablets, microtablets have the advantages of (1) being easy to swallow and suitable for children and the elderly; (2) having a small diameter, a smooth and beautiful surface, and accurate dosage; (3) having a simple preparation process, less coating consumables, and high efficiency; (4) having a small size, and being easy to transport, carry, and store; (5) having the advantages of both ordinary tablets and microcapsules; and (6) having a relatively simple taste masking technology for unpleasant drug tastes such as bitterness and astringency.

[0007] Patent CN116570581A discloses a pharmaceutical composition containing thiopronin with excellent stability and its preparation process. The pharmaceutical composition with excellent stability is a tablet, which contains cysteine ​​hydrochloride or cysteine ​​as an antioxidant, and corn starch with a moisture content of not more than 5.0%, accounting for not less than 0.1% of the prescription weight. In addition, the preparation process of the pharmaceutical composition is also disclosed. The technology of this invention is manifested in the use of cysteine ​​hydrochloride or cysteine ​​as an antioxidant for wet granulation, which improves the compressibility of the tablets and protects thiopronin from degradation under wet and hot conditions. At the same time, it is combined with dried corn starch to further improve the stability of the tablets under influencing factors and stability test processes, and inhibit the degradation of impurity III. The technical solution of this invention effectively solves the problem of rapid growth of disulfide impurities.

[0008] Patent CN104083332A discloses a tiopronin composition and a preparation method thereof, wherein the pharmaceutical composition comprises tiopronin, 20% dextran solution and L-aspartic acid; the pharmaceutical composition is prepared into a powder injection, 20% dextran (molecular weight 2×10 5 ) solution, mixed with tiopronin and L-aspartic acid at 4°C, divided into ampoules, freeze-dried and sealed. The powder injection is loose and porous, sponge-like, and dissolves quickly and completely after adding water, and almost immediately restores its original properties. The method for preparing the pharmaceutical composition into a preparation of the invention is suitable for large-scale production; the pharmaceutical composition prepared into a preparation has good stability.

[0009] Patent CN104163781A discloses a thiopronin special ultrafine powder freeze-dried preparation and a preparation method thereof, characterized in that 2-chloropropionic acid and phosphorus trichloride are used as raw materials to react to generate 2-chloropropionyl chloride, which is then reacted with glycine to generate 2-chloropropionyl glycine, which is then reacted with sodium disulfide, and then reduced with zinc powder to obtain a thiopronin crude product, which is refined, airflow ultrafinely ground, and freeze-dried. The thiopronin special ultrafine powder freeze-dried preparation of this invention has the advantages of good clarity, high stability, high purity, few impurities, small particles, large specific surface area, good solubility, small toxic and side effects, and not easy to be allergic.

[0010] Patent CN103705482A discloses a method for preparing tiopronin tablets. The method for preparing tiopronin tablets provided by the invention is characterized in that the auxiliary materials, diluents and disintegrants are first granulated with a binder and then dried, and then the tiopronin raw materials and the additional auxiliary materials are added and mixed before tableting. This can prevent the active ingredients in tiopronin from being damaged by moisture and heat during the traditional wet granulation process, thereby maintaining good drug stability; solves the problem that the traditional wet granulation process is not suitable for the production of tiopronin tablets; the prepared tiopronin tablets have low production cost and simple operation.

[0011] Patent CN102697750A discloses a sulphuric acid enteric-coated tablet and a preparation method thereof, characterized in that the sulphuric acid enteric-coated tablet (per 1000 tablets) comprises: sulphuric acid 96.5-108.0 g, microcrystalline cellulose 58.0-64.5 g, lactose 32.0-38.5 g, cross-linked polyvinylpyrrolidone 6.8-7.6 g, appropriate amount of polyvinylpyrrolidone K30 (9%-11% ethanol solution), magnesium stearate 2.7-3.3 g, silicon dioxide 1.8-2.2 g, coating powder 11.6-14.0 g, 75%-85% ethanol (w / w) 140.0-158.5 g. The present invention solves the problem that sulphuric acid enteric-coated tablets currently have no patent protection in China.

[0012] However, none of the above-mentioned prior arts can provide a composition and preparation method of tiopronin enteric-coated microtablets to solve the bottleneck technical problems of uneven content of active ingredients, unreasonable dissolution and unstable quality in the preparation process of tiopronin enteric-coated microtablets. Summary of the invention

[0013] In view of this, the prior art cannot solve the problems of uneven content of active ingredients, unreasonable dissolution and unstable quality in the preparation process of tiopronin enteric-coated microtablets. The present invention aims to provide a tiopronin enteric-coated microtablet and a preparation method.

[0014] To achieve the above-mentioned purpose of the invention, on the one hand, the present invention provides a sulpronin enteric-coated microtablet, which is composed of granules and a coating, wherein the granules are composed of sulpronin, a filler, a binder, a disintegrant, and a lubricant; and the coating is composed of a film-forming agent, an enteric coating, an anti-adhesive agent, and a plasticizer.

[0015] Preferably, the diameter of the tiopronin enteric-coated microtablets is 1-3 mm.

[0016] More preferably, and as an example of the present invention, the diameter of the tiopronin enteric-coated micro-tablets is 3 mm.

[0017] Preferably, the filler is a mixture of lactose and anhydrous calcium phosphate.

[0018] Wherein, the adhesive includes but is not limited to povidone, cellulose ether, gelatin and the like.

[0019] Preferably, the binder is selected from at least one of povidone, cellulose ether and gelatin.

[0020] More preferably, the binder is selected from one of povidone, cellulose ether and gelatin.

[0021] More preferably, the binder is selected from one of cellulose ethers.

[0022] Further preferably, and as an example of the present invention, the binder is hydroxypropyl cellulose.

[0023] The disintegrant includes but is not limited to carboxymethyl starch salt, cross-linked carboxymethyl cellulose salt, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, and the like.

[0024] Preferably, the disintegrant is selected from at least one of carboxymethyl starch salt, cross-linked carboxymethyl cellulose salt, polyvinyl pyrrolidone, and low-substituted hydroxypropyl cellulose.

[0025] More preferably, the disintegrant is selected from sodium carboxymethyl starch, cross-linked carboxymethyl cellulose salt, polyvinyl pyrrolidone, and low-substituted hydroxypropyl cellulose.

[0026] More preferably, and as an example of the present invention, the disintegrant is low-substituted hydroxypropylcellulose.

[0027] Wherein, the lubricant includes but is not limited to fatty acids, fatty acid salts, talcum powder and the like.

[0028] Preferably, the lubricant is selected from at least one of fatty acids, fatty acid salts and talc.

[0029] More preferably, the lubricant is selected from one of fatty acids, fatty acid salts and talc.

[0030] More preferably, the lubricant is selected from one of the stearates.

[0031] Further preferably, and as an example of the present invention, the lubricant is magnesium stearate.

[0032] Preferably, the film-forming agent is selected from at least one of a natural film-forming agent and a synthetic film-forming agent.

[0033] More preferably, the film-forming agent is at least one of synthetic film-forming agents.

[0034] More preferably, and as an example of the present invention, the film former is hypromellose.

[0035] The enteric coating includes, but is not limited to, cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl phthalate (PVAP), styrene maleic acid copolymer (StyMA), acrylic resin (Eudragit), and the like.

[0036] Preferably, the enteric coating is selected from at least one of cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl phthalate (PVAP), styrene maleic acid copolymer (StyMA), and acrylic resin (Eudragit).

[0037] More preferably, the enteric coating is selected from one of cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl phthalate (PVAP), styrene maleic acid copolymer (StyMA), and acrylic resin (Eudragit L).

[0038] More preferably, the enteric coating is acrylic resin Eudragit L.

[0039] Further preferably, and as an example of the present invention, the enteric coating is acrylic resin Eudragit L 100-55.

[0040] Wherein, the anti-sticking agent includes but is not limited to calcium carbonate, talcum powder, titanium dioxide, etc.

[0041] Preferably, the anti-sticking agent is selected from at least one of calcium carbonate, talc and titanium dioxide.

[0042] More preferably, the anti-sticking agent is selected from one of calcium carbonate, talc and titanium dioxide.

[0043] More preferably, and as an example of the present invention, the anti-sticking agent is talc.

[0044] Wherein, as an example of the present invention, the plasticizer is preferably triethyl citrate.

[0045] Preferably, the mass percentage of each component in the granules is: 24.9%-25.1% of tiopronin, 0.4%-4% of binder, 1%-5% of disintegrant, 0.4%-5.05% of lubricant, and the remainder is filler; the mass percentage of each component in the coating is: 1%-4% of film-forming agent, 3.44%-9% of enteric coating, 1%-4% of anti-adherent agent, and 0.11%-0.9% of plasticizer.

[0046] More preferably, the mass percentage of each component in the granules is: 24.9%-25.1% of tiopronin, 1.4%-2% of binder, 2.35%-2.85% of disintegrant, 1.9%-2.25% of lubricant, and the remainder is filler; the mass percentage of each component in the coating is: 2.39%-3% of film-forming agent, 5.06%-8.02% of enteric coating, 1.99%-3.4% of anti-adherent agent, and 0.42%-0.82% of plasticizer.

[0047] More preferably, the mass percentage of each component in the granules is: 24.9%-25% of tiopronin, 0.7%-1.7% of binder, 2.5%-2.84% of disintegrant, 2%-2.24% of lubricant, and the balance is filler; the mass percentage of each component in the coating is: 2.39%-3% of film-forming agent, 5.06%-6.8% of enteric coating, 1.99%-3.4% of anti-adherent agent, and 0.42%-0.7% of plasticizer.

[0048] Further preferably, the mass percentage of each component in the granules is: 25% of tiopronin, 1.7% of binder, 2.5% of disintegrant, 2% of lubricant, and the balance is filler; the mass percentage of each component in the coating is: 3% of film-forming agent, 6.8% of enteric coating, 3.4% of anti-adherent agent, and 0.7% of plasticizer.

[0049] Preferably, the filler is a mixture of lactose and anhydrous calcium phosphate.

[0050] More preferably, the mass ratio of lactose to anhydrous calcium phosphate is 11.79-13.74:0.1-1.

[0051] More preferably, the mass ratio of lactose to anhydrous calcium phosphate is 12.55-13.7:0.2-1.

[0052] Also preferably, the mass ratio of lactose to anhydrous calcium phosphate is 13.16-13.7:0.2-0.6.

[0053] Further preferably, the mass ratio of lactose to anhydrous calcium phosphate is 13.16:0.6.

[0054] Preferably, the binder is hydroxypropyl cellulose, and the disintegrant is low-substituted hydroxypropyl cellulose.

[0055] More preferably, the mass ratio of the hydroxypropyl cellulose to the low-substituted hydroxypropyl cellulose is 0.8-8:0.2-10.

[0056] More preferably, the mass ratio of the hydroxypropyl cellulose to the low-substituted hydroxypropyl cellulose is 1.4-5.4:4.7-5.7.

[0057] Also preferably, the mass ratio of the hydroxypropyl cellulose to the low-substituted hydroxypropyl cellulose is 1.4-3.4:5-5.7.

[0058] Further preferably, the mass ratio of the hydroxypropyl cellulose to the low-substituted hydroxypropyl cellulose is 3.4:5.

[0059] On the other hand, the present invention provides a method for preparing tiopronin enteric-coated microtablets, wherein the preparation method is selected from a fluidized bed preparation process, a wet preparation process, and a dry press preparation process.

[0060] Preferably, the preparation method is selected from a fluidized bed preparation process and a wet preparation process.

[0061] Preferably, the preparation method is a fluidized bed preparation process, comprising the following steps:

[0062] S1, whole grain sieving;

[0063] S2, fluidized bed granulation: dissolving the binder to obtain a binder solution, preheating, spraying the binder solution, and drying;

[0064] S3, mixing the whole granules, tableting, and obtaining granules;

[0065] S4, coating the granules obtained in step S3 to obtain tiopronin enteric-coated microtablets.

[0066] More preferably, the step S1 is specifically as follows:

[0067] Tiopronin, lactose and low-substituted hydroxypropyl cellulose were passed through a 1.0 mesh and granulated at 600 rpm.

[0068] More preferably, the step S2 is specifically as follows:

[0069] Dissolve hydroxypropyl cellulose in isopropanol and stir to obtain an adhesive solution. Set the heater temperature to 80°C, the inlet air temperature to 60°C, the material temperature to 40°C, and the fan frequency to 20Hz. When the material temperature is ≥38°C or the outlet air temperature is ≥40°C, pour the material in for preheating. Start spraying when the material temperature is ≥38°C, set the heater temperature to 100°C, the inlet air temperature to 65°C, and the material temperature to 40°C, maintain the actual material temperature between 32°C and 38°C, maintain the fan frequency at 25Hz to 35Hz, and the liquid supply speed at 10rpm to 45rpm. Discharge the material when the drying loss LOD is ≤2.0%.

[0070] More preferably, the step S3 is specifically as follows:

[0071] The granules were sized using a 1.0 mesh at 600 rpm. The granules were weighed to calculate the required amount of magnesium stearate and anhydrous calcium phosphate, and the granules were mixed at 20 rpm / min for 3 min, respectively, and tableted to obtain granules.

[0072] More preferably, the step S4 is specifically as follows:

[0073] (1) Preparation of Hydroxypropyl Methylcellulose Solution: Slowly add to isopropyl alcohol solution and stir to disperse evenly. (2) Preparation of Enteric Coating: Add Eudragit L to 95% ethanol and stir until dissolved and clarified, then add talcum powder and triethyl citrate and stir until uniform and continue stirring. (3) First spray the isolation layer of Hydroxypropyl Methylcellulose to the granules prepared in step S3 until the theoretical weight gain is 3%, and then spray the enteric coating to the theoretical weight gain of 9%. After drying, the finished product is obtained.

[0074] Preferably, the preparation method is a wet preparation process, comprising the following steps:

[0075] T1, whole grain sieving;

[0076] T2. Wet granulation: dissolving the binder to obtain a binder solution, premixing, slurrying, granulating, and dispersing;

[0077] T3, wet granulation, fluidized bed drying;

[0078] T4, dry granulation, total mixing, tableting, to obtain granules;

[0079] T5. Coating the granules obtained in step T4 to prepare tiopronin enteric-coated microtablets.

[0080] More preferably, the step T1 is specifically as follows:

[0081] Tiopronin, lactose and low-substituted hydroxypropyl cellulose were passed through a 1.0 mesh and granulated at 600 rpm.

[0082] More preferably, the step T2 is specifically as follows:

[0083] Dissolve hydroxypropyl cellulose in isopropanol solution and stir to obtain adhesive solution. Pour tiopronin, lactose and low-substituted hydroxypropyl cellulose into a pot for premixing, stir at 500 rpm, shear at 800 rpm, and mix for 15 minutes. Spray the prepared adhesive into the pot, with a peristaltic pump speed of 57 rpm, atomization pressure of 0.2 bar, stirring speed of 500 rpm, and shear speed of 800 rpm. Stir at 500 rpm, shear at 800 rpm, and granulate for about 129 seconds. Disperse at 500 rpm, shear at 800 rpm for 1 minute.

[0084] More preferably, the step T3 is specifically as follows:

[0085] Use a 6*6 screen to granulate at 1000rpm. Set the air inlet temperature to 45℃, the fan frequency to 75Hz, and the air inlet volume to 200m 3 / h, maintaining the material temperature below 42°C for drying, and discharging the material when the loss on drying (LOD) is ≤ 2.0%.

[0086] More preferably, the step T4 is specifically as follows:

[0087] The granules were sized using a 1.0 mesh at 1000 rpm. The granules were weighed to calculate the required amount of magnesium stearate and anhydrous calcium phosphate, and the mixtures were mixed at 20 rpm / min for 3 min and tableted to obtain the granule portion of tiopronin enteric-coated microtablets.

[0088] More preferably, the step T5 is specifically as follows:

[0089] (1): Preparation of Hydroxypropyl Methylcellulose Solution: Slowly add to isopropanol solution and stir until evenly dispersed. (2): Preparation of Enteric Coating: Add Eudragit L to 95% ethanol and stir until dissolved and clarified, then add talcum powder and triethyl citrate and stir until evenly dispersed and continue stirring. (3): First spray the isolation layer of Hydroxypropyl Methylcellulose to the granules prepared in step T4 until the theoretical weight gain is 3%, and then spray the enteric coating to increase the theoretical weight to 9%. After drying, the sulfopronil enteric microtablets are obtained.

[0090] Preferably, in the above preparation method, the concentration of the adhesive solution is 1%-10%.

[0091] More preferably, and as an example of the present invention, the concentration of the binder solution is 3%.

[0092] Preferably, the dry pressing machine preparation process comprises the following steps:

[0093] E1, sieving whole granules; E2, mixing and tableting to obtain granules; E3, coating the granules obtained in step E2 to obtain tiopronin enteric-coated microtablets.

[0094] More preferably, the step E1 is specifically as follows:

[0095] Tiopronin, lactose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose and anhydrous calcium phosphate were passed through a 1.0 mesh and granulated at 1000 rpm.

[0096] More preferably, the step E2 is specifically as follows:

[0097] The sieved material was placed in a mixer and mixed at 20 rpm / min for 20 min. Magnesium stearate was added and mixed at 20 rpm / min for 3 min, and tableted to obtain the granular part of tiopronin enteric-coated microtablets.

[0098] More preferably, the step E3 is specifically as follows.

[0099] (1) Preparation of Hydroxypropyl Methylcellulose Solution: Slowly add to isopropyl alcohol solution and stir to disperse evenly. (2) Preparation of Enteric Coating: Add Eudragit L to 95% ethanol and stir until dissolved and clarified, then add talcum powder and triethyl citrate and stir until uniform and continue stirring. (3) Spray the isolation layer of Hydroxypropyl Methylcellulose to the granules prepared in step E2 until the theoretical weight gain is 3%, and then spray the enteric coating to the theoretical weight gain of 9%. After drying, the finished product is obtained.

[0100] In another aspect, the present invention further provides the use of the above-mentioned tiopronin enteric-coated microtablets and / or preparation method in preparing tiopronin drugs.

[0101] Compared with the prior art, the present invention has the following beneficial effects:

[0102] (1) The present invention adds anhydrous calcium phosphate to the tablets, so that the tablet thickness uniformity is good and the weight difference meets the standard.

[0103] (2) The amount of filler used in the present invention is selected so that the active ingredient has a dissolution behavior that is not inferior to that of the reference preparation, especially rapid and complete dissolution in a medium in which the raw material drug is poorly soluble.

[0104] (3) The enteric-coated microtablets provided by the present invention are multi-unit preparations, which have the advantages of both ordinary tablets and micropills, have precise dosage, are easy to swallow, can improve patient compliance, and are particularly suitable for the elderly and children. Microtablets have higher product quality and economic benefits than tablet injections.

[0105] (4) The enteric-coated microtablets provided by the present invention have a small diameter, a smooth and beautiful surface, a small volume, are easy to transport, carry and store, and have broad application prospects. DETAILED DESCRIPTION

[0106] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is only an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the invention of the present invention based on the disclosed content, and they should also fall within the scope of the present invention.

[0107] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0108] In the following examples, some raw material information is as follows:

[0109] name Manufacturer / Source Tiopronin Hainan Satinine Hydroxypropylcellulose Ashland Low substituted hydroxypropyl cellulose Anhui Mountains and Rivers Hydroxypropyl methylcellulose Anhui Mountains and Rivers Eudragit L100-55 Shanghai Changwei talcum powder Si Baiquan

[0110] In the above table, the weight average molecular weight of the hydroxypropyl cellulose is 45000-90000; the hydroxypropoxy content of the low-substituted hydroxypropyl cellulose is 10%-12.9%; the methoxy content of the hydroxypropyl methylcellulose is 28%-30%, and the hydroxypropoxy content is 7%-12%.

[0111] Example 1-5: Tiopronin enteric-coated microtablets.

[0112] In Examples 1-5, the ingredients of each tiopronin enteric-coated micro-tablet are shown in the following table:

[0113]

[0114]

[0115] Comparative Example 1-3: Tiopronin enteric-coated microtablets.

[0116] In Comparative Examples 1-3, the composition of each Tiopronin enteric-coated micro-tablet is shown in the following table:

[0117] Ingredients / mg Comparative Example 1 Comparative Example 2 Comparative Example 3 Tiopronin 5 5 5 lactose 13.76 6.88 13.16 Anhydrous calcium phosphate 0 6.88 0.6 Hydroxypropylcellulose 0.34 0.34 0.82 Low substituted hydroxypropyl cellulose 0.5 0.5 0.02 Magnesium Stearate 0.4 0.4 0.4 Hydroxypropyl methylcellulose 0.6 0.6 0.5 Eudragit L 100-55 1.36 1.36 1.36 talcum powder 0.68 0.68 0.5 Triethyl citrate 0.14 0.14 0.12

[0118] Preparation Example 1: Preparation of tiopronin enteric-coated microtablets by fluidized bed preparation process.

[0119] Weigh all the raw materials and auxiliary materials except magnesium stearate according to the prescription amount. Pass tiopronin, lactose and low-substituted hydroxypropyl cellulose through a 1.0 mesh sieve and granulate at 600 rpm.

[0120] Prepare a 3% adhesive: slowly add hydroxypropyl cellulose into isopropyl alcohol at a stirrer speed of 600 rpm / h.

[0121] Granulation: Preheating: Set the heater temperature to 80℃, the air inlet temperature to 60℃, the material temperature to 40℃, and the fan frequency to 20Hz. When the material temperature is ≥38℃ or the air outlet temperature is ≥40℃, pour the material in for preheating. Spraying adhesive: Start spraying when the material temperature is ≥38℃, set the heater temperature to 100℃, the air inlet temperature to 65℃, the material temperature to 40℃, maintain the actual material temperature between 32℃ and 38℃, maintain the fan frequency at 25Hz to 35Hz, and the liquid supply speed at 10rpm to 45rpm. Drying: Discharge the material when LOD≤2.0%.

[0122] Use a 1.0 sieve to granulate at 600 rpm. Weigh the granules after granulation to calculate the amount of magnesium stearate and anhydrous calcium phosphate required, mix them for 3 minutes at 20 rpm / min, and tablet them to obtain the granular part of tiopronin enteric-coated microtablets. The granular part of tiopronin enteric-coated microtablets obtained by the method of Preparation Example 1 in Examples 1-5 and Comparative Examples 1-3 are respectively recorded as Example 1.1, Example 2.1, Example 3.1, Example 4.1, Example 5.1, Comparative Example 1.1, Comparative Example 2.1, and Comparative Example 3.1.

[0123] Coating. (1) Preparation of Hydroxypropyl Methylcellulose Solution: Slowly add to isopropyl alcohol solution and stir to disperse evenly. (2) Preparation of Enteric Coating: Add Eudragit L to 95% ethanol and stir until dissolved and clarified, then add talcum powder and triethyl citrate and stir until uniform and continue stirring. (3) First spray the isolation layer of Hydroxypropyl Methylcellulose to the previously prepared granules until the theoretical weight gain is 3%, and then spray the enteric coating to increase the theoretical weight to 9%. After drying, the enteric-coated microtablets of Tiopronin are obtained.

[0124] Preparation Example 2: Preparation of tiopronin enteric-coated microtablets by wet preparation technology.

[0125] Weigh all the raw materials and auxiliary materials except magnesium stearate according to the prescription amount. Pass tiopronin, lactose and low-substituted hydroxypropyl cellulose through a 1.0 mesh sieve and granulate at 600 rpm.

[0126] Prepare a 3% adhesive: slowly add hydroxypropyl cellulose into the isopropanol solution at a stirrer speed of 600 rpm / h.

[0127] Premixing: Pour tiopronin, lactose and low-substituted hydroxypropyl cellulose into the pot for premixing, stir at 500rpm, shear at 800rpm, and mix for 15min. Slurrying: Spray the prepared adhesive into the pot, peristaltic pump speed 57rpm, atomization pressure 0.2bar, stirring speed 500rpm, shear speed 800rpm. Granulation: Stirring speed 500rpm, shear speed 800rpm, granulation for about 129s. Dispersion: Disperse for 1min at stirring speed 500rpm, shear speed 800rpm.

[0128] Wet granulation: Use a 6*6 sieve at 1000rpm for granulation.

[0129] Fluidized bed drying: set the air inlet temperature to 45°C, the fan frequency to 75Hz, and the air inlet volume to 200m 3 / h, maintain the material temperature below 42°C for drying, and discharge when LOD≤2.0.

[0130] Dry granulation: granulation was performed using a 1.0 sieve at 1000 rpm.

[0131] Total mixing: Weigh the granules after granulation to calculate the amount of magnesium stearate and anhydrous calcium phosphate required, mix them at 20 rpm / min for 3 min, and tablet them to obtain the granule part of tiopronin enteric-coated microtablets. The granule parts of tiopronin enteric-coated microtablets obtained by the method of Preparation Example 2 in Examples 1-5 and Comparative Examples 1-3 are respectively recorded as Example 1.2, Example 2.2, Example 3.2, Example 4.2, Example 5.2, Comparative Example 1.2, Comparative Example 2.2, and Comparative Example 3.2.

[0132] Coating. (1): Preparation of Hydroxypropyl Methylcellulose Solution: Slowly add to isopropyl alcohol solution and stir until evenly dispersed. (2): Preparation of Enteric Coating: Add Eudragit L to isopropyl alcohol and stir until dissolved and clarified, then add talcum powder and triethyl citrate and stir until evenly dispersed and continue stirring. (3): First spray the isolation layer of Hydroxypropyl Methylcellulose to a theoretical weight gain of 3%, then spray the enteric coating to a theoretical weight gain of 9%. After drying, the enteric coated microtablets of Tiopronin are obtained.

[0133] Preparation Example 3: Preparation of tiopronin enteric-coated microtablets by dry pressing process.

[0134] Weigh each raw material and auxiliary material according to the prescription amount.

[0135] Tiopronin, lactose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose and anhydrous calcium phosphate were passed through a 1.0 mesh and granulated at 1000 rpm.

[0136] The sieved material is placed in a mixer and mixed at 20 rpm / min for 20 min. Magnesium stearate is added and mixed at 20 rpm / min for 3 min, and tableted, or after dry granulation, tableted to obtain the particle part of the enteric-coated micro-tablets of tiopronin. The particle parts of the enteric-coated micro-tablets of tiopronin obtained by the method of Preparation Example 3 in Examples 1-5 and Comparative Examples 1-3 are respectively recorded as Example 1.3, Example 2.3, Example 3.3, Example 4.3, Example 5.3, Comparative Example 1.3, Comparative Example 2.3, and Comparative Example 3.3.

[0137] Coating. (1): Preparation of Hydroxypropyl Methylcellulose Solution: Slowly add to isopropyl alcohol solution and stir until evenly dispersed. (2): Preparation of Enteric Coating: Add Eudragit L to isopropyl alcohol and stir until dissolved and clear, then add talcum powder and triethyl citrate and stir until evenly dispersed and continue stirring. (3): First spray the isolation layer of Hydroxypropyl Methylcellulose to a theoretical weight gain of 3%, then spray the enteric coating to a theoretical weight gain of 9%. After drying, the finished product is obtained.

[0138] In Preparation Examples 1 to 3, the diameter of the prepared tiopronin enteric-coated microtablets was 3 mm.

[0139] Effect Example

[0140] 1. Tablet weight distribution, tablet surface smoothness and hardness of the granular part of tiopronin enteric-coated microtablets.

[0141] For the enteric-coated microtablets of sulphuric acid, it is composed of a granular part and a coating part, wherein the granular part contains the active ingredient sulphuric acid of the drug. Therefore, the tablet weight difference distribution of the granular part obtained after tableting directly affects the tablet distribution uniformity of the active ingredient content in the enteric-coated microtablets of sulphuric acid, and thus affects the drug quality of the enteric-coated microtablets of sulphuric acid. In addition, the smoothness and hardness of the granular part have a direct impact on the appearance of the enteric-coated microtablets of sulphuric acid. In summary, it is necessary to evaluate the tablet weight distribution, tablet smoothness and hardness of the granular part in the enteric-coated microtablets of sulphuric acid prepared by different processes.

[0142] The specific method for evaluating tablet weight difference is as follows: take 10 tablets of the test sample, accurately weigh the total weight, and after obtaining the average tablet weight, accurately weigh each tablet separately, and compare the weight of each tablet with the average tablet weight. According to the 2020 edition of the Pharmacopoeia, the tablet weight difference should be within 7.5%, and no more than 2 tablets should exceed the weight difference limit, and no one tablet should exceed the limit by 1 times; those that meet the above provisions are recorded as qualified, and those that do not meet any of the above provisions are recorded as unqualified.

[0143] The specific method for evaluating the one-sided appearance is as follows: visually inspect for sticking and visible contaminants.

[0144] The specific evaluation method of friability index is as follows: weigh about 6.5g of plain tablets, blow away the powder from the tablets with a hair dryer, weigh accurately, put in a cylinder, and rotate 100 times. Take out, remove the powder in the same way, weigh accurately, and calculate the percentage of weight loss, which is the friability. The weight loss shall not exceed 1%, and no broken, cracked or crushed tablets shall be detected.

[0145] The evaluation results of the tablet weight distribution, tablet appearance, hardness and friability of the granular part of the Tiopronin enteric-coated microtablets prepared in Preparation Example 1-3 are shown in the following table:

[0146] Group One-sided appearance Tablet weight difference Hardness / N friability Example 1.1 No sticking qualified 24.81-27.62 0.09% Example 2.1 No sticking qualified 22.81-27.34 0.24% Example 3.1 Slight stickiness Failure 20.37-29.6 0.26% Example 4.1 Slight stickiness Failure 21.40-32.14 0.34% Example 5.1 Slight stickiness Failure 19.13-30.48 0.44% Comparative Example 1.1 Obvious sticking Failure 18.44-33.81 0.63% Comparative Example 2.1 Slight stickiness Failure 19.97-28.98 0.41% Comparative Example 3.1 Slight stickiness Failure 20.88-34.14 0.33% Example 1.2 No sticking qualified 24.22-27.64 0.13% Example 2.2 No sticking qualified 21.15-27.81 0.28% Example 3.2 No sticking qualified 19.76-25.78 0.25% Example 4.2 Slight stickiness Failure 18.90-26.78 0.49% Example 5.2 Slight stickiness Failure 17.99-26.74 0.52% Comparative Example 1.2 Obvious sticking Failure 19.99-29.03 0.67% Comparative Example 2.2 Slight stickiness Failure 18.69-28.47 0.48% Comparative Example 3.2 Slight stickiness Failure 17.87-30.73 0.57% Example 1.3 No sticking qualified 25.90-28.98 0.16% Example 2.3 Slight stickiness qualified 21.94-28.07 0.33% Example 3.3 Slight stickiness Failure 20.90-27.59 0.37% Example 4.3 Slight stickiness Failure 20.14-32.87 0.59% Example 5.3 Slight stickiness Failure 19.76-31.88 0.54% Comparative Example 1.3 Obvious sticking Failure 18.70-30.75 0.71% Comparative Example 2.3 Slight stickiness Failure 19.78-31.19 0.54% Comparative Example 3.3 Slight stickiness Failure 20.09-30.11 0.61%

[0147] From the experimental results in the above table, we can see that:

[0148] First, under the condition of selecting the same preparation process, the granular part of the enteric-coated microtablets provided in the examples in each group is superior to the corresponding comparative example group in terms of tablet appearance, tablet weight difference, hardness and friability indexes, which indicates that the content of each component in the granular part of the enteric-coated microtablets provided in Examples 1-5 of the present invention is reasonably selected, which is superior to the enteric-coated microtablets provided in Comparative Examples 1-3; in particular, Comparative Example 1 does not use anhydrous calcium phosphate as a filler, and its granular part has obvious sticking phenomenon, which greatly affects the drug-making process of the enteric-coated microtablets.

[0149] Second, when the drug formulation is the same (such as Example 1.1, Example 1.2, Example 1.3), different preparation processes are selected, and the sheet appearance, tablet weight difference, hardness and friability index of the granule part of the enteric-coated micro-tablets obtained are also different. In particular, when the formula is the same, the granule part of the enteric-coated micro-tablets prepared by the dry press preparation process (Examples 1.3-5.3, Comparative Examples 1.3-3.3) has more sticking and punching phenomena, while the granule part prepared by the fluidized bed preparation process and the wet preparation process has a relatively good sheet appearance.

[0150] 2. Simulated dissolution performance of tiopronin enteric-coated microtablets.

[0151] The dissolution effects of the Tiopronin enteric-coated micro-tablets before and after coating in each embodiment and comparative example were measured. The Tiopronin enteric-coated micro-tablets in each embodiment and comparative example were prepared by the method described in Preparation Example 1.

[0152] The specific method of dissolution effect test is as follows: Acid dissolution: 750ml of 0.1mol / L hydrochloric acid solution is measured and placed in each dissolution cup. The deviation between the actual measured volume and the specified volume should be within the range of ±1%. When the temperature of the dissolution medium is constant at 37℃±0.5℃, take 6 tablets (granules) of the test sample and put them into the dissolution cup respectively. Start the instrument at a speed of 50r / min. After 2 hours, absorb an appropriate amount of dissolution liquid at the specified sampling point and filter it. The sampling to filtration should be completed within 30 seconds. Determine according to the method specified under each variety, and calculate the acid dissolution amount of each tablet. Dissolution in buffer solution: Add 250ml of pH6.8 sodium phosphate solution with a temperature of 37℃±0.5℃ to the above acid solution, continue to operate for 45 minutes, absorb an appropriate amount of dissolution liquid at the specified sampling point, filter it, and the sampling to filtration should be completed within 30 seconds. Determine according to the method specified under each variety, and calculate the buffer dissolution amount of each tablet.

[0153] The effects are shown in the following table:

[0154]

[0155]

[0156] It can be seen from the test results in the above table that the coated thiopronin enteric-coated microtablets can achieve the enteric-coated effect under simulated conditions, while the granular part of the uncoated thiopronin enteric-coated microtablets dissolves significantly in the simulated gastric environment and cannot achieve the enteric-coated effect.

[0157] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in the field do not depart from the scope of protection of the present invention.

Claims

1. A tiopronin enteric-coated microtablet, characterized in that: The invention is composed of granules and coatings, wherein the granules are composed of tiopronin, a filler, a binder, a disintegrant and a lubricant; and the coatings are composed of a film-forming agent, an enteric coating, an anti-adhesive agent and a plasticizer; The filler is a mixture of lactose and anhydrous calcium phosphate, the binder is hydroxypropyl cellulose, the disintegrant is low-substituted hydroxypropyl cellulose, the lubricant is magnesium stearate, the film-forming agent is hydroxypropyl methylcellulose, the enteric coating is acrylic resin Eudragit L, the anti-adherent is talc, and the plasticizer is triethyl citrate; The mass percentage of each component in the granules is: 24.9%-25% of tiopronin, 0.7%-1.7% of binder, 2.5%-2.84% of disintegrant, 2%-2.24% of lubricant, and the balance is filler; The mass percentage of each component in the coating to the mass percentage of the particles is: film former 2.39%-3%, enteric coating 5.06%-6.8%, anti-adherent 1.99%-3.4%, plasticizer 0.42%-0.7%; The mass ratio of lactose to anhydrous calcium phosphate is 13.16-13.7:0.2-0.

6.

2. The tiopronin enteric-coated microtablet according to claim 1, characterized in that: The diameter of the tiopronin enteric-coated micro-tablets is 1-3 mm.

3. The tiopronin enteric-coated microtablet according to claim 1, characterized in that: The mass percentage of each component in the particle to the mass percentage of the particle is: Tiopronin 25%, binder 1.7%, disintegrant 2.5%, lubricant 2%, and the balance is filler; The mass percentage of each component in the coating to the mass percentage of the particles is: Film former 3%, enteric coating 6.8%, anti-adherent 3.4%, plasticizer 0.7%.

4. A method for preparing a tiopronin enteric-coated microtablet according to any one of claims 1 to 3, characterized in that: The preparation method is selected from a fluidized bed preparation process, a wet preparation process, and a dry press preparation process; Wherein, the fluidized bed preparation process comprises the following steps: S1, sieving the whole granules; S2, fluidized bed granulation: dissolving the binder to obtain a binder solution, granulating, spraying the binder solution, and drying; S3, mixing the whole granules, tableting, and obtaining granules; S4, coating the particles obtained in step S3 to obtain tiopronin enteric-coated microtablets; The wet preparation process comprises the following steps: T1. Screening of whole granules; T2. Wet granulation: dissolving the binder to obtain a binder solution, premixing, slurrying, granulating, and dispersing; T3, wet granulation, fluidized bed drying; T4, dry granulation, total mixing, tableting, to obtain granules; T5. Coating the granules obtained in step T4 to prepare tiopronin enteric-coated microtablets.

5. The preparation method according to claim 4, characterized in that: The concentration of the adhesive solution in step S2 and step T2 is 1%-10%.

6. Use of the enteric-coated microtablets of tiopronin according to any one of claims 1 to 3 or the preparation method according to any one of claims 4 to 5 in the preparation of tiopronin medicines.

Citation Information

Cited By

  • Tiopronin composition and preparation method thereof

    CN121987582A